Generic omeprazole adds a new option for equine gastric disease: full analysis

Version 2

Treatment approaches for equine gastric disease are evolving less because of a brand-new therapeutic class than because of better disease differentiation, growing scrutiny of formulation quality, and a fresh FDA approval that could affect access. On April 6, 2026, the FDA approved Gastrobim, the first generic omeprazole oral paste for gastric ulcers in horses and foals 4 weeks and older, clearing a lower-cost entrant into a market long dominated by Gastrogard and UlcerGard. (fda.gov)

That matters because equine gastric disease is now approached as at least two clinically distinct problems: equine squamous gastric disease and equine glandular gastric disease. Reviews and veterinary references consistently note that these conditions differ in lesion distribution, risk factors, and treatment response. Squamous disease is closely tied to acid exposure, intermittent feeding, and training intensity, while glandular disease appears more complex, with inflammation, mucosal defense failure, and sometimes poorer response to standard acid suppression alone. A newer retrospective study adds that they may also look different in the exam room: physical clinical signs were more commonly associated with ESGD, while behavioral and mixed signs were more often seen in horses with EGGD or mixed ulceration. Gastroscopy remains the diagnostic standard, and treatment still depends on knowing which mucosa is affected. (merckvetmanual.com)

The key pharmacology remains familiar. FDA says Gastrobim, like Gastrogard, is indicated for treatment at 4 mg/kg once daily for four weeks, followed by a lower maintenance dose for recurrence prevention. Merck Veterinary Manual also describes omeprazole as the only FDA-approved medication for both treatment and prevention of recurrence of equine gastric ulcers in horses, while noting that glandular disease often prompts adjunctive use of sucralfate or misoprostol. That distinction is important in practice: the strongest evidence base for omeprazole is in prevention and treatment of squamous disease, particularly in horses in active training. A meta-analysis of randomized trials found prophylactic omeprazole substantially reduced ulcer occurrence compared with sham treatment. (fda.gov)

At the same time, newer data underscore the limits of a one-size-fits-all approach. The Wiley-published trial cited in the source set found that a lecithin-pectin-meadowsweet nutraceutical did not significantly prevent ulcer recurrence on gastroscopy after omeprazole treatment, even though salivary biomarkers suggested possible mucosal effects. Reporting on a 2023 Journal of Veterinary Internal Medicine study, The Horse also said medium-term omeprazole treatment did not support the common assumption that tapering is needed after courses of eight weeks or less because clinically meaningful rebound hyperacidity has not been demonstrated in the same way as in people. And the newer clinical-sign data are a reminder that presentation itself can vary by lesion location: in that retrospective series of 52 scoped horses, ulcer severity was not associated with sign type, while sport activity was associated with both ulcer location and whether signs were physical, behavioral, or mixed. (thehorse.com)

Industry and regulatory signals are also shaping the conversation. FDA’s approval of a bioequivalent generic may reduce pressure to use compounded omeprazole products, an issue regulators have flagged repeatedly when approved horse formulations are available. In 2025, FDA correspondence tied to compounding policy specifically referenced compounded omeprazole paste as a copy of an approved equine product, and trade coverage has continued to highlight concerns that cheaper compounded pastes may not deliver reliable absorption or legal compliance. (fda.gov)

Why it matters: For veterinary professionals, this story is really about matching the right product and protocol to the right disease, while improving adherence. A generic oral paste could help some pet parents and trainers stay on label and complete full treatment and prevention courses. But lower price alone won’t solve the harder clinical problem: glandular disease remains more frustrating to manage, and horses often need concurrent changes in forage access, starch intake, exercise timing, stress, and NSAID exposure. The literature also suggests clinicians should be careful about overpromising nutraceuticals, because biomarker changes have not yet translated into consistent endoscopic benefit. And because newer evidence suggests ESGD may skew more toward physical signs while EGGD may present more behaviorally, vague “ulcer signs” still should not substitute for lesion-specific diagnosis. (fda.gov)

Another practical implication is case selection and follow-up. Because clinical signs are nonspecific, empirical treatment without scoping can blur the difference between treatment failure, recurrence, and misdiagnosis. That’s especially relevant in referral and sport-horse practice, where poor performance, girthiness, appetite change, or behavioral signs may prompt ulcer treatment even when lesion type, or the presence of ulcers at all, is uncertain. Recent research and reviews continue to support a more disciplined approach: scope when possible, classify lesions, treat appropriately, and reassess if the horse does not respond as expected. The newer retrospective study supports that caution by showing associations between sign pattern and ulcer location, but not between sign pattern and ulcer severity, meaning presentation may help raise suspicion without replacing gastroscopy. (merckvetmanual.com)

What to watch: Over the next year, watch for whether generic omeprazole changes real-world prescribing and compliance, whether more comparative data emerge for glandular-disease protocols such as omeprazole plus sucralfate or misoprostol, whether clinicians begin to use emerging sign-pattern data to triage which horses get scoped sooner, and whether regulators further tighten pressure on compounded copies now that an FDA-approved generic is on the market. (fda.gov)